University of Illinois Urbana-Champaign researchers developed lolamicin, an experimental antibiotic that targets a protein transport system in Gram-negative bacteria. In mouse studies it fought resistant infections while largely sparing gut microbes, but safety and effectiveness in people remain untested.
TLDR: Lolamicin, an experimental antibiotic from University of Illinois researchers, targeted disease-causing Gram-negative bacteria in laboratory and mouse studies. Unlike broad-spectrum comparators, it largely spared mice’s gut microbes and did not trigger the same vulnerability to C. difficile infection. Human safety and effectiveness are not yet established.
A laboratory-developed antibiotic called lolamicin has shown an unusual ability to attack disease-causing bacteria while leaving many beneficial gut microbes largely intact in animal tests. The finding, reported by researchers at the University of Illinois Urbana-Champaign in 2024, offers a possible way to address a costly side effect of many antibiotics: damage to the microbiome that can leave patients vulnerable to further illness.
Lolamicin targets a protein transport system found in Gram-negative bacteria. These microbes include pathogens responsible for pneumonia, bloodstream infections and urinary tract infections. The transporter, known as the Lol system, helps move lipoproteins to the outer surface of bacterial cells, a step important for maintaining their protective outer membrane.
The research team screened compounds for their ability to interfere with that system and developed lolamicin from an initial chemical lead. In laboratory experiments, the compound killed a range of disease-causing Gram-negative bacteria, including strains resistant to multiple existing antibiotics. It did not act against Gram-positive bacteria, which lack the same transport system.
That selectivity matters because broad-spectrum antibiotics can disrupt helpful organisms along with pathogens. When the normal gut community is depleted, Clostridioides difficile can multiply and cause severe diarrhea and inflammation. Antibiotic exposure can also alter the microbiome in ways that persist after treatment ends.
To test whether lolamicin could preserve gut microbes, the researchers compared its effects with those of other antibiotics in mice. Animals treated with lolamicin retained a gut microbial community more similar to that of untreated mice. In a separate experiment, mice were first given antibiotics that make them susceptible to C. difficile infection. Lolamicin treatment did not produce the same increase in susceptibility seen with the comparator drugs.
The team also tested the compound in mouse models of infection. Lolamicin protected mice from a bloodstream infection caused by a resistant strain of Escherichia coli and from pneumonia caused by Klebsiella pneumoniae. These results suggest the compound can work in living animals, not only in dishes of cultured bacteria.
The discovery addresses a difficult target. Gram-negative bacteria have an outer membrane that blocks many drugs from entering, and their ability to develop resistance has made infections increasingly challenging to treat. The World Health Organization has identified drug-resistant Gram-negative pathogens as a major research priority. A drug that reaches a bacterial target while sparing unrelated microbes could broaden treatment options and reduce some collateral effects of therapy.
Still, lolamicin is an experimental compound, not an approved medicine. Its safety and effectiveness have been demonstrated only in preclinical work, and animal results do not establish that a drug will be safe or beneficial in people. Researchers will need to refine the molecule, evaluate how it is absorbed and distributed, and determine whether it causes toxic effects at doses needed to treat infection.
Resistance is another open question. Bacteria can evolve changes that blunt antibiotic activity, including changes to drug targets or mechanisms that pump compounds out of cells. Further studies must establish how readily pathogens can become resistant to lolamicin and whether combining it with other medicines would help preserve its effectiveness.
The work, led by chemistry professor Paul Hergenrother and published in Nature, is an early demonstration that antibiotics may be designed around a particular bacterial system rather than used as indiscriminate microbial killers. If later studies confirm the approach, selective drugs could make treatment more precise and help protect the microbial communities that support health. The next step is further preclinical testing before any consideration of trials in humans.

